FHACT® takes the guess work out of cervical cancer screening

WATCH THE VIDEO >

Get answers,
get FHACT®.
Webinar series.

LEARN MORE >

FHACT® is indicated for HPV-positive ASCUS and LSIL patients.

LEARN MORE >

FHACT® is the only FISH Probe to assess four biomarkers associated with cervical cancer.

Learn More

Latest News

23 Jun 16

Cancer Genetics, Inc. and Sayre Therapeutics Announce Distribution Agreement to Commercialize CGI’s Proprietary FDA-cleared Tissue of Origin (TOO®) Test Throughout India and South Asia (read more...)

- TOO® is the ONLY FDA-cleared test of its type, used to aid in identifying challenging tumors, including metastatic, poorly differentiated, and (read more...)
07 Jun 16

Cancer Genetics, Inc. to Present at the 2016 LD Micro Invitational Investor Conference (read more...)

- RUTHERFORD, N.J., June 07, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling (read more...)

Events

Clinicians
Patients